Phathom Pharmaceuticals (PHAT) Operating Leases (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Operating Leases data on file, last reported at $2.0 million in Q1 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.1 million, changed N/A from the prior year.
• Operating Leases for Q1 2026 stood at $2.0 million, down from $2.1 million in the prior quarter.
• Over the last five years, Operating Leases for PHAT reached as high as $2.1 million in Q3 2025 and fell as low as $133000.0 in Q2 2024.
• Historically, Operating Leases has averaged $1.1 million across 5 years, with a median of $1.0 million in 2022.
• Across the five-year window, Operating Leases sank 83.14% in 2024 and surged 342.86% in 2025, its largest moves.
• Year by year, Operating Leases stood at $1.1 million in 2022, then slumped by 57.92% to $462000.0 in 2023, then slumped by 71.21% to $133000.0 in 2024, then soared by 1452.63% to $2.1 million in 2025, then fell by 5.04% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $2.0 million in Q1 2026, $2.1 million in Q4 2025, and $2.1 million in Q3 2025.